HEOR & VALUE EVIDENCE STRATEGY
Decision-led HEOR and value evidence strategy that connects clinical innovation to payer, HTA and access requirements across the asset lifecycle.
THE STRATEGIC QUESTION
More evidence does not automatically create more value. VELA helps teams focus investment on the questions decision-makers will ask, then connect individual studies and analyses into an integrated evidence strategy.
HOW WE CAN HELP
VELA advises pharmaceutical and biotechnology teams on integrated HEOR and evidence strategies that connect asset development, payer expectations and evidence priorities across the lifecycle.
Our approach sequences economic, outcomes and real-world evidence priorities around asset milestones, helping teams focus investment on the questions that matter for access and lifecycle decisions.
Effective evidence planning requires alignment across clinical development, HEOR, medical affairs and market access. VELA helps identify critical evidence gaps, distinguish decision-relevant uncertainties from lower-priority questions and translate priorities into integrated evidence plans.
Senior strategic review of study protocols, analysis plans and partner deliverables helps keep planned activities aligned with the wider evidence strategy and the decisions they must inform.
VELA helps teams interpret payer and health technology assessment (HTA) expectations for comparative effectiveness, economic value and patient-relevant outcomes, and assess their implications for evidence planning.
We provide strategic perspective on the relevance and limitations of existing and planned evidence, highlighting uncertainties that may affect HTA readiness, value assessment and payer confidence.
A credible value narrative connects clinical differentiation, economic relevance, patient outcomes and real-world evidence with the needs of decision-makers.
VELA helps translate complex evidence into coherent value narratives and payer-relevant frameworks, clarifying what the evidence supports, where uncertainty remains and how findings can inform access discussions.
DELIVERABLES
Evidence that informs strategy. Value that supports decisions.
Each engagement focuses on the evidence questions, asset milestones and decision-making needs of your team. Depending on the advisory scope, deliverables may include:
A decision-led roadmap linking HEOR and evidence priorities to asset development milestones, payer questions and lifecycle objectives, with a clear sequence of strategic evidence needs.
A structured review of existing and planned clinical, economic, outcomes and real-world evidence, identifying critical gaps and priorities for cross-functional evidence planning.
A framework mapping comparative effectiveness, economic value, patient-relevant outcomes and evidence uncertainty to relevant payer and HTA expectations.
A structured approach connecting clinical, economic and real-world evidence to a credible value narrative, with clear messages, supporting evidence and limitations relevant to payer decisions.
Our commitment: Independent senior-level HEOR perspective, clear evidence priorities and practical strategic guidance to support informed access decisions.
WHEN TO ENGAGE
START A CONVERSATION
From early evidence planning to HTA readiness and value communication, VELA helps biopharma teams connect evidence priorities with the decisions that shape patient access.
Discuss Your Evidence Strategy ↗Connect with VELA Access Partners to explore how focused HEOR and value evidence advisory can support your asset and strategic priorities.